Lee Voulters, MD
Neurology · Gulfport, MSNPI 1669417705
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 575 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations.
Across 575 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Acadia Pharmaceuticals Inc$1K
- Novartis$875
- Amgen$731
- Pfizer$479
- Teva Pharmaceuticals USA, Inc.$432
- plus $4K from 41 others
What the payments were for
- Food & beverage$9,099100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,108 in reported general payments places this provider in the 65th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 18 | $502,220 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 23 | $365,731 |
| IngrezzaValbenazine Tosylate | 27 | $215,340 |
| Avonex (4 Pack)Interferon Beta-1a | 27 | $211,651 |
| Kesimpta PenOfatumumab | 19 | $176,665 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $133,390 |
| Aimovig AutoinjectorErenumab-Aooe | 109 | $108,491 |
| AustedoDeutetrabenazine | 16 | $98,183 |
| RytaryCarbidopa/Levodopa | 54 | $95,652 |
| NuplazidPimavanserin Tartrate | 19 | $92,465 |
| BriviactBrivaracetam | 35 | $52,387 |
| NamzaricMemantine Hcl/Donepezil Hcl | 38 | $29,197 |
| XcopriCenobamate | 13 | $27,761 |
| Carbamazepine ErCarbamazepine | 137 | $25,903 |
| UbrelvyUbrogepant | 14 | $25,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Eliquis, Dilantin | $479 | $544,98089 claims |
| Grifols USA, LLCGamunex-C | $18 | $365,73123 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $90 | $215,34027 claims |
| BiogenAvonex (4 Pack) | $42 | $211,65127 claims |
| CSL BehringPrivigen | $18 | $133,39012 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $432 | $98,18316 claims |
| Amneal Pharmaceuticals LLCRytary | $40 | $95,65254 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,021 | $92,46519 claims |
| AbbVieNamzaric, Ubrelvy, Qulipta, Botox | $1,886 | $90,05077 claims |
| UCB, Inc.Briviact | $425 | $52,38735 claims |
| SK Life Science, Inc.Xcopri | $238 | $27,76113 claims |
| Kyowa Kirin, Inc.Nourianz | $19 | $21,35012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 neurology providers in Mississippi.
Other neurology in Gulfport
- Chelsea GrowGulfport$78K
- Abha MishraGulfport$12K
- Diane RossGulfport$10K
- Stephen LandyTupelo$1.9M
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Ronald SchwartzHattiesburg$352K
- Rajesh SharmaJackson$152K
- Paula WarrenHattiesburg$114K
- Justin GraffTupelo$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.